Sanofi on Friday published sharply higher results in 2021, still boosted by its flagship treatment Dupixent, which continues to serve as a locomotive, allowing it to again increase the amount of dividends that will be paid to its shareholders.
Read alsoSanofi, GSK, Gilead, MSD…: these giants who missed the vaccination boat
In detail, net profit is down nearly 50%, to 6.22 billion euros.
Last year, it was boosted by the sale of a large part of Sanofi's shares in biotech Regeneron.
But net profit from activities, the indicator favored by the group, which excludes exceptional effects, rose by 11.8%, to 8.21 billion euros.